Optic Neuropathy Market Size Report For 2016 By Radiant Insights, Inc
Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H1 2016', provides an overview of the Optic Neuropathy pipeline landscape. Read More @ http://www.radiantinsights.com/research/optic-neuropathy-pipeline-review-h1-2016
Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H1 2016', provides an overview of the Optic Neuropathy pipeline landscape.
Read More @ http://www.radiantinsights.com/research/optic-neuropathy-pipeline-review-h1-2016
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Optic</strong> <strong>Neuropathy</strong> - Pipeline Review, H1 <strong>2016</strong> <strong>By</strong> <strong>Radiant</strong><br />
<strong>Insights</strong><br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Pipeline Review, H1 <strong>2016</strong><br />
Summary<br />
Global <strong>Market</strong>s Direct's, '<strong>Optic</strong> <strong>Neuropathy</strong> - Pipeline Review, H1 <strong>2016</strong>', provides an overview of the<br />
<strong>Optic</strong> <strong>Neuropathy</strong> pipeline landscape.<br />
The report provides comprehensive information on the therapeutics under development for <strong>Optic</strong><br />
<strong>Neuropathy</strong>, complete with analysis by stage of development, drug target, mechanism of action (MoA),<br />
route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological<br />
action of the therapeutics, its complete research and development history and latest news and press<br />
releases. Additionally, the report provides an overview of key players involved in therapeutic<br />
development for <strong>Optic</strong> <strong>Neuropathy</strong> and features dormant and discontinued projects.<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/optic-neuropathypipeline-review-h1-<strong>2016</strong><br />
Global <strong>Market</strong>s Direct's report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from Global<br />
<strong>Market</strong>s Direct's proprietary databases, company/university websites, clinical trial registries,<br />
conferences, SEC filings, investor presentations and featured press releases from company/university<br />
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic<br />
review following a stringent set of processes to ensure that all the profiles are updated with the latest<br />
set of information. Additionally, various dynamic tracking processes ensure that the most recent<br />
developments are captured on a real time basis.<br />
The report helps in identifying and tracking emerging players in the market and their portfolios,<br />
enhances decision making capabilities and helps to create effective counter strategies to gain<br />
competitive advantage.<br />
Note*: Certain sections in the report may be removed or altered based on the availability and relevance<br />
of data.<br />
Scope
- The report provides a snapshot of the global therapeutic landscape of <strong>Optic</strong> <strong>Neuropathy</strong><br />
- The report reviews pipeline therapeutics for <strong>Optic</strong> <strong>Neuropathy</strong> by companies and universities/research<br />
institutes based on information derived from company and industry-specific sources<br />
- The report covers pipeline products based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages<br />
- The report features descriptive drug profiles for the pipeline products which includes, product<br />
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental<br />
activities<br />
- The report reviews key players involved <strong>Optic</strong> <strong>Neuropathy</strong> therapeutics and enlists all their major and<br />
minor projects<br />
- The report assesses <strong>Optic</strong> <strong>Neuropathy</strong> therapeutics based on drug target, mechanism of action (MoA),<br />
route of administration (RoA) and molecule type<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- The report reviews latest news related to pipeline therapeutics for <strong>Optic</strong> <strong>Neuropathy</strong><br />
Reasons to buy<br />
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D<br />
strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Optic</strong><br />
<strong>Neuropathy</strong><br />
- Identify potential new clients or partners in the target demographic<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline<br />
therapeutics<br />
- Devise corrective measures for pipeline projects by understanding <strong>Optic</strong> <strong>Neuropathy</strong> pipeline depth<br />
and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with<br />
the most attractive projects to enhance and expand business potential and Scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors<br />
that drove them from pipeline<br />
Buy a Sample copy of This <strong>Report</strong> @ http://www.radiantinsights.com/checkout/167922<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 5<br />
List of Figures 5<br />
Introduction 6<br />
Global <strong>Market</strong>s Direct <strong>Report</strong> Coverage 6<br />
<strong>Optic</strong> <strong>Neuropathy</strong> Overview 7<br />
Therapeutics Development 8<br />
Pipeline Products for <strong>Optic</strong> <strong>Neuropathy</strong> - Overview 8<br />
Pipeline Products for <strong>Optic</strong> <strong>Neuropathy</strong> - Comparative Analysis 9
<strong>Optic</strong> <strong>Neuropathy</strong> - Therapeutics under Development by Companies 10<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Therapeutics under Investigation by Universities/Institutes 11<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Pipeline Products Glance 12<br />
Late Stage Products 12<br />
Clinical Stage Products 13<br />
Early Stage Products 14<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Products under Development by Companies 15<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Products under Investigation by Universities/Institutes 16<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Companies Involved in Therapeutics Development 17<br />
BioAxone BioSciences, <strong>Inc</strong>. 17<br />
Inotek Pharmaceuticals Corporation 18<br />
Neurotech Pharmaceuticals, <strong>Inc</strong>. 19<br />
PharmatrophiX, <strong>Inc</strong>. 20<br />
Quark Pharmaceuticals, <strong>Inc</strong>. 21<br />
Regenera Pharma Ltd. 22<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Therapeutics Assessment 23<br />
Assessment by Monotherapy Products 23<br />
Assessment by Target 24<br />
Assessment by Mechanism of Action 26<br />
Assessment by Route of Administration 28<br />
Assessment by Molecule Type 30<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/optic-neuropathypipeline-review-h1-<strong>2016</strong><br />
About Us:<br />
<strong>Radiant</strong> <strong>Insights</strong> <strong>Inc</strong>. is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
Contact Details:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
28 2nd Street,<br />
Suite 3036 San Francisco,<br />
CA 94105 United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Website: http://www.radiantinsights.com/<br />
Email: sales@radiantinsights.com
Change language